FAK drives resistance to therapy in HPV-negative head and neck cancer in a p53-dependent manner.
P. M. Pifer, L. Yang, M. Kumar, T. Xie, M. Frederick, A. Hefner, B. Beadle, D. Molkentine, J. Molkentine, A. Dhawan, M. Abdelhakiem, A. A. Osman, J. N. Myers, C. R. Pickering, V. C. Sandulache, , H. D. Skinner
This study identifies FAK as a driver of therapy resistance in HPV-negative HNSCC, showing its role is dependent on mutant TP53.
bioRxiv · Jun 3, 2022Cancer Biology